A study of HPN424 for the treatment of prostate cancer.
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs HPN 424 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 25 May 2017 According to a Harpoon Therapeutics media release, the company expects to enter phase I clinical trials in 2018.
- 30 Jan 2017 New trial record